Literature DB >> 33743630

Study on the COVID-19 infection status, prevention and control strategies among people entering Shenzhen.

Xuan Zou1, Zi-Qian Xu1, Hai-Rui Wang1, Bi-Xin Wang1, Jian-Fan He1,2, Jing-Zhong Wang3.   

Abstract

BACKGROUND: The novel coronavirus disease 2019 (COVID-19) confirmed cases overseas have continued to rise in the last months, and many people overseas have chosen to return to China. This increases the risk of a large number of imported cases which may cause a relapse of the COVID-19 outbreak. In order to prevent imported infection, the Shenzhen government has implemented a closed-loop management strategy using nucleic acid testing (NAT) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and requiring 14 days of medical observation for individuals with an overseas tour history (Hong Kong, Macao, Taiwan province and other countries). Our study aims to describe the status of COVID-19 infection among people entering Shenzhen, and to evaluate the effect of the closed-loop management strategy.
METHODS: We undertook a descriptive study and risk analysis by the entry time, time of reporting, and local confirmed cases in countries of origin. The NAT were completed in Shenzhen Center for Disease Control and Prevention (CDC), ten district-level CDCs, and fever clinics.
RESULTS: A total of 86,844 people from overseas entered Shenzhen from January 1 to April 18, 2020; there were 39 imported COVID cases and 293 close contacts. The infection rate of people entering was 4.49‰ [95% Confidence interval (CI): 3.26‰-6.05‰]. Fourteen imported cases (35.9%) came from the UK, and nine (23.08%) came from the USA. People entering from the USA since March 9 or from the UK since March 13 are the high-risk population. As of July 17, there have been no new confirmed cases in Shenzhen for 153 days, and the numbers of confirmed case, close contacts, and asymptomatic cases are 0.
CONCLUSIONS: The closed-loop management has been effective in preventing imported infection and controlling domestic relapse. The distribution of entry time and report time for imported cases overseas was similar. This shows that it is important to implement closed-loop management at the port of entry.

Entities:  

Keywords:  COVID-19; Closed-loop management; Imported cases; Prevention and control; SARS-CoV-2

Mesh:

Year:  2021        PMID: 33743630      PMCID: PMC7980727          DOI: 10.1186/s12889-021-10548-8

Source DB:  PubMed          Journal:  BMC Public Health        ISSN: 1471-2458            Impact factor:   3.295


  6 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

Authors:  Qun Li; Xuhua Guan; Peng Wu; Xiaoye Wang; Lei Zhou; Yeqing Tong; Ruiqi Ren; Kathy S M Leung; Eric H Y Lau; Jessica Y Wong; Xuesen Xing; Nijuan Xiang; Yang Wu; Chao Li; Qi Chen; Dan Li; Tian Liu; Jing Zhao; Man Liu; Wenxiao Tu; Chuding Chen; Lianmei Jin; Rui Yang; Qi Wang; Suhua Zhou; Rui Wang; Hui Liu; Yinbo Luo; Yuan Liu; Ge Shao; Huan Li; Zhongfa Tao; Yang Yang; Zhiqiang Deng; Boxi Liu; Zhitao Ma; Yanping Zhang; Guoqing Shi; Tommy T Y Lam; Joseph T Wu; George F Gao; Benjamin J Cowling; Bo Yang; Gabriel M Leung; Zijian Feng
Journal:  N Engl J Med       Date:  2020-01-29       Impact factor: 176.079

3.  First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment.

Authors:  Kathy Leung; Joseph T Wu; Di Liu; Gabriel M Leung
Journal:  Lancet       Date:  2020-04-08       Impact factor: 79.321

4.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

5.  Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries.

Authors:  Nirmal Kandel; Stella Chungong; Abbas Omaar; Jun Xing
Journal:  Lancet       Date:  2020-03-18       Impact factor: 79.321

6.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  6 in total
  4 in total

1.  Correction to: Study on the COVID-19 infection status, prevention and control strategies among people entering Shenzhen.

Authors:  Xuan Zou; Zi-Qian Xu; Hai-Rui Wang; Bi-Xin Wang; Jian-Fan He; Jing-Zhong Wang
Journal:  BMC Public Health       Date:  2021-05-12       Impact factor: 3.295

Review 2.  Could mouth rinses be an adjuvant in the treatment of SARS-CoV-2 patients? An appraisal with a systematic review.

Authors:  Gargi Gandhi; Latha Thimmappa; Nagaraja Upadhya; Sunitha Carnelio
Journal:  Int J Dent Hyg       Date:  2021-10-29       Impact factor: 2.725

3.  The governance of imported 2019-nCov infections: What can be learned from China's experience?

Authors:  Hao Li; Jiaxin He; Jiayu Chen; Shuning Pan; Jiehan Feng; Shuang Liu
Journal:  Glob Health Res Policy       Date:  2022-03-09

4.  Implementation and challenges to preventing the re-establishment of malaria in China in the COVID-19 era.

Authors:  Guangyu Lu; Yuanyuan Cao; Dongying Zhang; Yuying Zhang; Yuhui Xu; Yan Lu; Qi Chen; Guoding Zhu; Jun Yan; Olaf Müller; Jun Cao
Journal:  Global Health       Date:  2022-06-21       Impact factor: 10.401

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.